CONCLUSIONS: These findings provide preclinical rationale for phase II evaluation of mithramycin in mesothelioma patients. PMID: 26459178 [PubMed - as supplied by publisher] (Source: Clin Med Res)
from MedWorm: Mesothelioma http://ift.tt/1Pz0N5e
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
ad
Enregistrer un commentaire